TSLA
Tesla
-- 230.580 NVDA
NVIDIA
-- 108.760 PLTR
Palantir
-- 78.050 AAPL
Apple
-- 220.840 GRRR
Gorilla Technology
-- 26.990 
News
$ZyVersa Therapeutics (ZVSA.US)$ ZyVersa Therapeutics Announces Peer-Reviewed Publication Demonstrating That Inflammasome ASC Inhibitor IC 100 Protects Against Stroke-Related Cardiovascular Injury and Dysfunction in Preclinical Trial
1 MINUTE AGO, 7:55 AM EST
VIA GLOBENEWSWIRE
• Strokes affect 795,000 people annually in the US. Obesity, a top risk factor for strokes, is associated with around one out of five strokes.
• Cardiac complications following a stroke are a leading cause of mortality and morbidity, second only to acute neurological injury.
• The pathomechanism underlying cardiac dysfunction following a stroke includes a surge of catecholamines, such as epinephrine, which induces inflammasome activation triggering a systemic inflammatory response.
• The published data showed that following a stroke, Inflammasome ASC Inhibitor IC 100 blocked AIM2 inflammasome activation and cell death (pyroptosis) in the heart and improved cardiac function.
• Data from this article support ZyVersa's development of Inflammasome ASC Inhibitor IC 100 for obesity and its associated cardiovascular comorbidities.
1 MINUTE AGO, 7:55 AM EST
VIA GLOBENEWSWIRE
• Strokes affect 795,000 people annually in the US. Obesity, a top risk factor for strokes, is associated with around one out of five strokes.
• Cardiac complications following a stroke are a leading cause of mortality and morbidity, second only to acute neurological injury.
• The pathomechanism underlying cardiac dysfunction following a stroke includes a surge of catecholamines, such as epinephrine, which induces inflammasome activation triggering a systemic inflammatory response.
• The published data showed that following a stroke, Inflammasome ASC Inhibitor IC 100 blocked AIM2 inflammasome activation and cell death (pyroptosis) in the heart and improved cardiac function.
• Data from this article support ZyVersa's development of Inflammasome ASC Inhibitor IC 100 for obesity and its associated cardiovascular comorbidities.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Paddyal : very strange.. it is tanking even with this good news
Trytosaveabit OP Paddyal : Big short low volume! Plus some taking profit from bag holding
Paddyal : I am stuck!! Will it even go up?what's your opinion?
Trytosaveabit OP Paddyal : It’s all volume/market interest! Gotta see! Wish I could answer that.